drugset / Trial / NCT01055015

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

NCT01055015

Phase 3 Completed 141 enrolled QRxPharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 3, two-arm, double-blind study of efficacy and safety of Q8003 in patients who have undergone primary unilateral total knee arthroplasty

Timeline

Start
2010-02
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 3 mg
Subject Morphine Other / unclassified 6 mg
Subject Morphine Other / unclassified 24 mg
Subject Oxycodone Other / unclassified 2 mg
Subject Oxycodone Other / unclassified 4 mg
Subject Oxycodone Other / unclassified 16 mg

Indications

No indication recorded.